Leonard B. Weiner
State University of New York Upstate Medical University
119 Papers
1.4K Citations
Leonard B. Weiner is an academic researcher from State University of New York Upstate Medical University. The author has contributed to research in topics: Medicine & Palivizumab. The author has an hindex of 41, co-authored 118 publications. Previous affiliations of Leonard B. Weiner include University of Colorado Hospital & Syracuse University.
Chat about Author
Papers
Valganciclovir for Symptomatic Congenital Cytomegalovirus Disease
David W. Kimberlin,Penelope Jester,Pablo J. Sánchez,Amina Ahmed,Ravit Arav-Boger,Marian G. Michaels,Negar Ashouri,Janet A. Englund,Benjamin Estrada,Richard F. Jacobs,Jose R. Romero,Sunil K. Sood,M. S. Whitworth,Mark J. Abzug,Mary T. Caserta,Sandra L. Fowler,Jorge Lujan-Zilbermann,Gregory A. Storch,Roberta L. DeBiasi,Jin Young Han,April Palmer,Leonard B. Weiner,Joseph A. Bocchini,Penelope H. Dennehy,Adam Finn,Paul D. Griffiths,Suzanne Luck,Kathleen Gutierrez,Natasha B. Halasa,James Homans,Andi L. Shane,Mike Sharland,Kari A. Simonsen,John A. Vanchiere,Charles R. Woods,Diane L. Sabo,Inmaculada Aban,Hui-Chien Kuo,Scott H. James,Mark N. Prichard,Jill Griffin,Dusty Giles,Edward P. Acosta,Richard J. Whitley +43 more
TL;DR: Treating symptomatic congenital CMV disease with valganciclovir for 6 months, as compared with 6 weeks, did not improve hearing in the short term but appeared to improve hearing and developmental outcomes modestly in the longer term.
Newborn Screening for Severe Combined Immunodeficiency in 11 Screening Programs in the United States
Antonia Kwan,Roshini S. Abraham,Robert Currier,Amy Brower,Karen Andruszewski,Jordan K. Abbott,Mei W. Baker,Mark Ballow,Louis Bartoshesky,Francisco A. Bonilla,Charles D. Brokopp,Edward G. Brooks,Michele Caggana,Jocelyn Celestin,Joseph A. Church,Anne Marie Comeau,James A. Connelly,Morton J. Cowan,Charlotte Cunningham-Rundles,Trivikram Dasu,Nina Dave,Maria Teresa de la Morena,Ulrich A. Duffner,Chin-To Fong,Lisa R. Forbes,Lisa R. Forbes,Debra Freedenberg,Erwin W. Gelfand,Jaime E. Hale,I. Celine Hanson,I. Celine Hanson,Beverly N. Hay,Diana Hu,Anthony J. Infante,Daisy Johnson,Neena Kapoor,Denise M. Kay,Donald B. Kohn,Rachel Lee,Heather K. Lehman,Zhili Lin,Fred Lorey,Aly Abdel-Mageed,Adrienne Manning,Sean A. McGhee,Sean A. McGhee,Theodore B. Moore,Stanley J. Naides,Luigi D. Notarangelo,Jordan S. Orange,Jordan S. Orange,Sung-Yun Pai,Matthew H. Porteus,Matthew H. Porteus,Ray Rodriguez,Neil Romberg,John M. Routes,Mary Ruehle,Arye Rubenstein,Carlos A. Saavedra-Matiz,Ginger Scott,Patricia M. Scott,Elizabeth Secord,Christine M. Seroogy,William T. Shearer,William T. Shearer,Subhadra Siegel,Stacy K. Silvers,E. Richard Stiehm,Robert W. Sugerman,John L. Sullivan,Susan Tanksley,Millard L. Tierce,James W. Verbsky,Beth Vogel,Rosalyn Walker,Kelly Walkovich,Jolan E. Walter,Richard L. Wasserman,Michael S. Watson,Geoffrey A. Weinberg,Leonard B. Weiner,Heather Wood,Anne B. Yates,Jennifer M. Puck +84 more
TL;DR: Newborn screening in 11 programs in the United States identified SCID in 1 in 58,000 infants, with high survival, and the usefulness of detection of non-SCID T-cell lymphopenia by the same screening remains to be determined.
Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infections.
David W. Kimberlin,Chin Yu Lin,Richard F. Jacobs,Dwight A. Powell,Lawrence Corey,William C. Gruber,Mobeen H. Rathore,John S. Bradley,Pamela S. Diaz,Mary L. Kumar,Ann M. Arvin,Kathleen Gutierrez,Mark Shelton,Leonard B. Weiner,John W. Sleasman,Teresa Murguı́a de Sierra,Stephen Weller,Seng-Jaw Soong,Jan Kiell,Fred D. Lakeman,Richard J. Whitley +20 more
TL;DR: An open-label evaluation of intravenous acyclovir at dosages higher than the 30 mg/kg/d standard dosage approved by the US Food and Drug Administration indicated that the survival rate for patients treated with HD acy Clovir was statistically significantly higher than for patientstreated with SD acyClovir.
543
Natural History of Neonatal Herpes Simplex Virus Infections in the Acyclovir Era
David W. Kimberlin,Chin-Yu Lin,Richard F. Jacobs,Dwight A. Powell,Lisa M. Frenkel,William C. Gruber,Mobeen H. Rathore,John S. Bradley,Pamela S. Diaz,Mary L. Kumar,Ann M. Arvin,Kathleen Gutierrez,Mark Shelton,Leonard B. Weiner,John W. Sleasman,Teresa Murguı́a de Sierra,Seng-Jaw Soong,Jan Kiell,Fred D. Lakeman,Richard J. Whitley +19 more
TL;DR: Comparisons between patients treated in the periods between 1981-1988 and 1989-1997 according to extent of disease revealed that the mean time between the onset of disease symptoms and initiation of therapy has not changed significantly from the early 1980s to the late 1990s, demonstrating that no progress has been made in decreasing the interval between onset of HSV symptoms and initiated antiviral therapy.
Prevention of respiratory syncytial virus infections: Indications for the use of palivizumab and update on the use of RSV-IGIV
Neal A. Halsey,Jon S. Abramson,P. Joan Chesney,Margaret C. Fisher,Michael A. Gerber,S. Michael Marcy,Dennis L. Murray,Gary D. Overturf,Charles G. Prober,Thomas N. Saari,Leonard B. Weiner,Richard J. Whitley,Robert F. Breiman,M. Carolyn Hardegree,A. Hirsch,Richard F. Jacobs,Noni E MacDonald,Walter A. Orenstein,N. Regina Rabinovich,B. Schwartz,Georges Peter,Carol J. Baker,Larry K. Pickering,H. Cody Meissner,James A. Lemons,Lillian R. Blackmon,William P. Kanto,H. M. MacDonald,Carol Miller,Lu Ann Papile,Warren Rosenfeld,Craig T. Shoemaker,Michael E. Speer,Michael F. Greene,Solomon Iyasu,Patricia Johnson,Douglas D. McMillan,Linda L. Wright,Jacob C. Langer,David K. Stevenson +39 more
TL;DR: Recommendations for its use are based on a large, randomized study demonstrating a 55% reduction in the risk of hospitalization attributable to respiratory syncytial virus (RSV) infections in high-risk pediatric patients, and discontinuation of injections for adverse events related to palivizumab was rare.
418